Ligand Pharmaceuticals Incorporated Stock News

The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positiv

It may sound counterintuitive but if you want big gains, you have to think small, as in small-cap stocks. Here, the idea is to trade predictability for maximum profit potential.

Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy

Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $73.60, marking a +0.68% move from the previous day.

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $68.64, indicating a -0.88% shift from the previous trading day.

Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $73.11, indicating a +1.25% shift from the previous trading day.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy

Ligand Pharmaceuticals (LGND) reachead $71.93 at the closing of the latest trading day, reflecting a -1.14% change compared to its last close.

Ligand (LGND) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often

Ligand Pharmaceuticals (LGND) reports encouraging fourth-quarter results as earnings and sales beat estimates. Management reiterates the 2024 financial outlook.

Ligand Pharmaceuticals (LGND) reachead $72.37 at the closing of the latest trading day, reflecting a -1.75% change compared to its last close.